Companies Davita Inc
Davita (DVA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Davita Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers59th pct.Of 17 peer CEOs
CEO pay, last three years
- $6,712,328FY2023
- $21,807,489FY2024
- $18,210,597FY2025
CEO total pay was $18,210,597 in fiscal 2025, down from $21,807,489 in fiscal 2024.
FY2025: salary $1,500,000 · bonus $0 · stock awards $11,442,481 · option awards $2,699,982
Executives and directors
James Hearty · Chief Compliance OfficerJavier Rodriguez · CEOKathleen Waters · General CounselDavid Maughan · COOJoel Ackerman · CFOAdam H. Schechter · Independent DirectorBarbara J. Desoer · Independent DirectorCharles G. Berg · Former director (through FY2025)Dennis W. Pullin · Independent DirectorGregory J. Moore, M.D., Ph.D · Independent DirectorJason M. Hollar · Independent DirectorPamela M. Arway · Chair of the BoardPhyllis R. Yale · Independent DirectorWendy L. Schoppert · Independent Director
Frequently asked questions
Who was the highest-paid executive at Davita Inc in fiscal 2025?
As disclosed, Javier Rodriguez (Chief Executive Officer) was the highest-paid executive at Davita Inc in fiscal 2025, with total compensation of $18,210,597.
How does Davita Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Javier Rodriguez's total compensation ranked at the 59th percentile of Davita Inc's disclosed peer group.
What is Davita Inc's CEO-to-median employee pay ratio?
As disclosed, Davita Inc's CEO-to-median employee pay ratio was 254:1.
How did shareholders vote on Davita Inc's executive compensation?
As disclosed, 98.52% of shareholders supported Davita Inc's executive compensation in the latest say-on-pay vote.
How much does Davita Inc spend in total on board compensation for fiscal 2025?
As disclosed, Davita Inc reported total board compensation of $3,223,986 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Javier Rodriguez | $1,500,000 | $0 | $11,442,481 | $2,699,982 | $2,089,491 | $0 | $478,643 | $18,210,597 |
| Chief Executive Officer | ||||||||
| Joel Ackerman | 834,616 | 0 | 3,644,589 | 860,008 | 774,063 | 0 | 16,686 | 6,129,962 |
| Chief Financial Officer and Treasurer | ||||||||
| David Maughan | 725,000 | 0 | 3,178,454 | 750,001 | 686,330 | 0 | 252,474 | 5,592,259 |
| Chief Operating Officer, DaVita Kidney Care | ||||||||
| Kathleen Waters | 750,000 | 0 | 2,034,334 | 479,982 | 662,664 | 0 | 16,665 | 3,943,645 |
| Chief Legal and Public Affairs Officer | ||||||||
| James Hearty | 600,000 | 0 | 720,420 | 170,012 | 455,331 | 0 | 16,352 | 1,962,115 |
| Chief Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Javier Rodriguez | $18,210,597 | $21,807,489 | $6,712,328 | ↓ −3,596,892 |
| Joel Ackerman | 6,129,962 | 6,349,613 | 6,868,181 | ↓ −219,651 |
| David Maughan | 5,592,259 | 4,933,138 | — | ↑ +659,121 |
| Kathleen Waters | 3,943,645 | 4,651,393 | 5,607,577 | ↓ −707,748 |
| James Hearty | 1,962,115 | 2,336,899 | 2,733,385 | ↓ −374,784 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee believes that our executive compensation program should emphasize performance and align our NEOs' interests with those of our stockholders, including with relation to financial performance, operational performance and relative stock price performance.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Javier Rodriguez | PSU | 2025-03-15 | 14,116 | 56,465 | — | 112,930 | $8,742,465 |
| David Maughan | RSU | 2025-03-15 | — | — | 5,228 | — | 749,957 |
| David Maughan | PSU | 2025-03-15 | 3,921 | 15,685 | — | 31,370 | 2,428,497 |
| Joel Ackerman | PSU | 2025-03-15 | 4,496 | 17,985 | — | 35,970 | 2,784,606 |
| Kathleen Waters | PSU | 2025-03-15 | 2,510 | 10,039 | — | 20,078 | 1,554,350 |
| James Hearty | PSU | 2025-03-15 | 889 | 3,555 | — | 7,110 | 550,432 |
| Kathleen Waters | RSU | 2025-03-15 | — | — | 3,346 | — | 479,984 |
| James Hearty | RSU | 2025-03-15 | — | — | 1,185 | — | 169,988 |
| Javier Rodriguez | RSU | 2025-03-15 | — | — | 18,822 | — | 2,700,016 |
| Javier Rodriguez | OPTION | 2025-03-15 | — | — | 52,106 | — | 2,699,982 |
| Joel Ackerman | RSU | 2025-03-15 | — | — | 5,995 | — | 859,983 |
| Kathleen Waters | OPTION | 2025-03-15 | — | — | 9,263 | — | 479,982 |
| Joel Ackerman | OPTION | 2025-03-15 | — | — | 16,597 | — | 860,008 |
| David Maughan | OPTION | 2025-03-15 | — | — | 14,474 | — | 750,001 |
| James Hearty | OPTION | 2025-03-15 | — | — | 3,281 | — | 170,012 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Javier Rodriguez | $2,700,016 | $8,742,465 | $2,699,982 | 61.8% |
| David Maughan | 749,957 | 2,428,497 | 750,001 | 61.8% |
| Joel Ackerman | 859,983 | 2,784,606 | 860,008 | 61.8% |
| Kathleen Waters | 479,984 | 1,554,350 | 479,982 | 61.8% |
| James Hearty | 169,988 | 550,432 | 170,012 | 61.8% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Hearty | RSU | 723 | — | $82,140 |
| James Hearty | RSU | 1,185 | — | 134,628 |
| James Hearty | RSU | 1,756 | — | 199,499 |
| Kathleen Waters | RSU | 1,989 | — | 225,970 |
| James Hearty | RSU | 2,488 | — | 282,662 |
| James Hearty | Option | 2,892 | 110.63 | — |
| James Hearty | Option | 3,281 | 143.45 | — |
| Kathleen Waters | RSU | 3,346 | — | 380,139 |
| Kathleen Waters | RSU | 4,829 | — | 548,623 |
| David Maughan | RSU | 5,228 | — | 593,953 |
| Joel Ackerman | RSU | 5,995 | — | 681,092 |
| Joel Ackerman | RSU | 6,585 | — | 748,122 |
| Kathleen Waters | RSU | 7,025 | — | 798,110 |
| James Hearty | RSU | 7,110 | — | 807,767 |
| James Hearty | RSU | 7,365 | — | 836,738 |
| James Hearty | RSU | 7,464 | — | 847,985 |
| Kathleen Waters | Option | 7,954 | 110.63 | — |
| Kathleen Waters | Option | 9,263 | 143.45 | — |
| Joel Ackerman | RSU | 10,977 | — | 1,247,097 |
| David Maughan | RSU | 12,203 | — | 1,386,383 |
| David Maughan | Option | 14,474 | 143.45 | — |
| Joel Ackerman | Option | 16,597 | 143.45 | — |
| David Maughan | RSU | 17,145 | — | 1,947,843 |
| Kathleen Waters | RSU | 18,411 | — | 2,091,674 |
| Javier Rodriguez | RSU | 18,822 | — | 2,138,367 |
| Kathleen Waters | RSU | 20,078 | — | 2,281,062 |
| James Hearty | RSU | 20,533 | — | 2,332,754 |
| Kathleen Waters | RSU | 21,074 | — | 2,394,217 |
| Joel Ackerman | Option | 21,694 | 110.63 | — |
| David Maughan | RSU | 21,954 | — | 2,494,194 |
| Joel Ackerman | RSU | 23,672 | — | 2,689,376 |
| Javier Rodriguez | RSU | 24,949 | — | 2,834,456 |
| David Maughan | RSU | 31,370 | — | 3,563,946 |
| Joel Ackerman | RSU | 32,930 | — | 3,741,177 |
| David Maughan | RSU | 35,508 | — | 4,034,064 |
| Joel Ackerman | RSU | 35,970 | — | 4,086,552 |
| Kathleen Waters | RSU | 51,330 | — | 5,831,601 |
| Javier Rodriguez | Option | 52,106 | 143.45 | — |
| Joel Ackerman | RSU | 65,997 | — | 7,497,919 |
| Javier Rodriguez | RSU | 112,268 | — | 12,754,767 |
| Javier Rodriguez | RSU | 112,930 | — | 12,829,977 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Pamela M. ArwayIndependent · Board Chair · Compensation · Nominating and Governance | $302,500 | $199,949 | $0 | $0 | $0 | $502,449 |
| Barbara J. DesoerIndependent · Compensation (Chair) · Audit | 190,000 | 199,949 | 0 | 0 | 0 | 389,949 |
| Phyllis R. YaleIndependent · Nominating and Governance (Chair) · Compliance and Quality | 180,000 | 199,949 | 0 | 0 | 0 | 379,949 |
| Gregory J. Moore, M.D., Ph.DIndependent · Compliance and Quality (Chair) · Nominating and Governance | 180,000 | 199,949 | 0 | 0 | 0 | 379,949 |
| Jason M. HollarIndependent · Audit (Chair) | 177,500 | 199,949 | 0 | 0 | 0 | 377,449 |
| Wendy L. SchoppertIndependent · Audit · Compensation | 140,000 | 199,949 | 0 | 0 | 0 | 339,949 |
| Adam H. SchechterIndependent · Audit · Compensation | 137,500 | 199,949 | 0 | 0 | 0 | 337,449 |
| Dennis W. PullinIndependent · Compliance and Quality · Nominating and Governance | 122,500 | 199,949 | 0 | 0 | 0 | 322,449 |
| Charles G. BergIndependent · Nominating and Governance · Compliance and Quality · Not standing for re-election · Departed during FY | 58,132 | 136,262 | 0 | 0 | 0 | 194,394 |
| Javier J. RodriguezEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $100,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | Five times the annual Board cash retainer, which for 2024 was $100,000, or $500,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,488,132 |
| Equity awards (grant-date value) | $1,735,854 |
| All other compensation | $0 |
| Total cost of the board | $3,223,986 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Davita as a peer
Companies that benchmark against DVA
18 companies name DVA as a compensation peer
- agilon health, inc.AGLFY2025
- Alignment Healthcare, Inc.ALHCFY2025
- Ardent Health, Inc.ARDTFY2025
- BAXTER INTERNATIONAL INCBAXFY2025
- BrightSpring Health Services, Inc.BTSGFY2025
- COMMUNITY HEALTH SYSTEMS INCCYHFY2025
- CVS HEALTH CorpCVSFY2025
- Encompass Health CorpEHCFY2025
- HENRY SCHEIN INCHSICFY2025
- HUMANA INCHUMFY2025
- MOLINA HEALTHCARE, INC.MOHFY2025
- Option Care Health, Inc.OPCHFY2025
- Oscar Health, Inc.OSCRFY2025
- QUEST DIAGNOSTICS INCDGXFY2025
- TENET HEALTHCARE CORPTHCFY2025
- UNIVERSAL HEALTH SERVICES INCUHSFY2025
Each company listed discloses DVA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DVA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
IQV IQVIA HoldingsHOLX HologicTHC Tenet HealthcareCNC CenteneLH Labcorp Holdings Inc.RVTY RevvityAVTR AvantorBAX Baxter InternationalXRAY Dentsply SironaEHC Encompass HealthHCA HCA HealthcareHSIC Henry ScheinMOH Molina HealthcareDGX Quest DiagnosticsSEM Select Medical HoldingsUHS Universal Health ServicesZBH Zimmer Biomet Holdings
Peer reciprocity
Of the companies Davita Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
— IQVIA Holdings (IQV)90— Hologic (HOLX)91✓ Tenet Healthcare (THC)92— Centene (CNC)93— Labcorp Holdings Inc. (LH)94— Revvity (RVTY)95— Avantor (AVTR)96✓ Baxter International (BAX)97— Dentsply Sirona (XRAY)98✓ Encompass Health (EHC)99— HCA Healthcare (HCA)100✓ Henry Schein (HSIC)101✓ Molina Healthcare (MOH)102✓ Quest Diagnostics (DGX)103 Select Medical Holdings (SEM)✓ Universal Health Services (UHS)104— Zimmer Biomet Holdings (ZBH)105
Reciprocity shown where the peer’s own current proxy has been read — each mark is cited in the register to that peer’s filing. A dash means the peer’s current proxy was read and names no reciprocal group including Davita Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Tenet Healthcare | 2025 | Saum Sutaria | $1,500,000 | $31,677,365 | $0 | $9,000,000 | $43,108,969 |
| 2 | Baxter International | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 3 | Iqvia Holdings | 2025 | Ari Bousbib | 1,800,000 | 15,749,957 | 4,528,317 | 4,966,127 | 28,128,245 |
| 4 | HCA Healthcare | 2025 | Samuel Hazen | 1,577,815 | 8,474,543 | 8,514,090 | 5,416,732 | 26,456,606 |
| 5 | Centene | 2025 | Sarah London | 1,473,077 | 15,537,733 | 0 | 2,109,446 | 19,506,298 |
| 6 | Molina Healthcare | 2025 | Joseph Zubretsky | 1,600,000 | 16,199,988 | 0 | 0 | 18,340,783 |
| 7 | Labcorp Holdings Inc. | 2025 | Adam Schechter | 1,435,000 | 11,400,463 | 2,754,582 | 2,062,095 | 18,339,913 |
| 8 | Davita Inc | 2025 | Javier Rodriguez | 1,500,000 | 11,442,481 | 2,699,982 | 2,089,491 | 18,210,597 |
| 9 | Universal Health Services | 2025 | Marc Miller | 1,430,769 | 9,999,904 | 0 | 4,292,307 | 16,148,937 |
| 10 | Zimmer Biomet Holdings | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 11 | Hologic | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 12 | Quest Diagnostics | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 13 | Revvity | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 14 | Henry Schein | 2025 | Stanley Bergman | 1,707,000 | 7,764,800 | 0 | 2,289,251 | 12,013,915 |
| 15 | Encompass Health | 2025 | Mark Tarr | 1,100,000 | 5,285,381 | 1,165,376 | 2,581,525 | 10,297,258 |
| 16 | Dentsply Sirona | 2025 | Daniel Scavilla | 431,753 | 3,484,488 | 3,221,523 | 437,150 | 8,760,139 |
| 17 | Avantor | 2025 | Emmanuel Ligner | 379,297 | 2,499,990 | 2,499,998 | 330,038 | 5,895,624 |
| 18 | Select Medical Holdings | 2025 | Thomas Mullin | 618,000 | 1,425,000 | 0 | 939,360 | 3,042,527 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Davita Inc | 93% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR v. S&P Health Care Services Select Industry Index | Compensia |
| Avantor | not disclosed | PSU 50 · Options 25 · RSU 25 | Yes — TSR Relative to Comparator Group | FW Cook |
| Baxter International | not disclosed | PSU 50 · RSU 25 · Option 25 | No | Aon |
| Centene | 71.6% | PSU 60 · RSU 40 | Yes — Relative TSR | FW Cook |
| Dentsply Sirona | 66% | PSU 50 · Options 50 | No | Frederic W. Cook & Co., Inc. |
| Encompass Health | 173.8% | PSU 60 · RSU 20 · Options 20 | No | Pay Governance |
| HCA Healthcare | 195.78% | SAR 50 · PSU 50 | No | Semler Brossy |
| Henry Schein | 89.3% | PSU 65 · RSU 35 | No | Pearl Meyer |
| Hologic | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Iqvia Holdings | not disclosed | PSU 75 · Options 25 | Yes | Meridian Compensation Partners, LLC |
| Labcorp Holdings Inc. | 95.8% | PSU 60 · RSU 20 · Options 20 | Yes — RELATIVE TSR MODIFIER | FW Cook |
| Molina Healthcare | not disclosed | PSU 60 · RSU 40 | No | FW Cook |
| Quest Diagnostics | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| Revvity | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Select Medical Holdings | 190% | RSU 100 | not disclosed | not disclosed |
| Tenet Healthcare | 200% | PSU 60 · RSU 40 | No | Meridian Compensation Partners, LLC |
| Universal Health Services | 200% | RSU 50 · PSU 50 | No | FW Cook |
| Zimmer Biomet Holdings | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 51,716,491 | 776,849 | 58,589 | 98.52% | Passed |
| 2025 | 2025-06-05 | 59,322,425 | 3,527,754 | 264,572 | 94.39% | Passed |
| 2024 | 2024-06-06 | 67,973,191 | 3,733,987 | 70,433 | 94.79% | Passed |
| 2023 | 2023-06-06 | 70,087,651 | 3,646,453 | 71,394 | 95.05% | Passed |
| 2022 | 2022-06-09 | 73,732,100 | 4,851,929 | 72,682 | 93.83% | Passed |
| 2021 | 2021-06-10 | 73,599,931 | 14,978,780 | 147,269 | 83.09% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 98.52%a |
| 2025 | 2025-06-05 | 94.39%b |
| 2024 | 2024-06-06 | 94.79%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 254 : 1 |
|---|---|
| CEO total compensation | $18,233,679 |
| Median employee compensation | $71,839 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| BERKSHIRE HATHAWAY INC | Greater-than-10% holder | 2026-05-01 | D | 1,220,376 | $150 | $182,864,679 | Common, indirect | Form 4 ↗ |
| James Hearty | Chief Compliance Officer | 2026-05-06 | D | 2,184 | 175 | 381,916 | Common | Form 4 ↗ |
| Joel Ackerman | CFO and Treasurer | 2026-05-07 | D | 51,471 | 192 | 9,887,528 | Common, open-market sale | Form 4 ↗ |
| David Maughan | Chief Operating Officer, DKC | 2026-05-11 | D | 7,073 | 199 | 1,408,581 | Common, open-market sale | Form 4 ↗ |
| David Maughan | Chief Operating Officer, DKC | 2026-05-12 | D | 13,456 | 199 | 2,681,162 | Common, open-market sale | Form 4 ↗ |
| James Hearty | Chief Compliance Officer | 2026-05-14 | D | 5,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Hearty | Chief Compliance Officer | 2026-05-14 | D | 1,117 | 198 | 221,278 | Common | Form 4 ↗ |
| James Hearty | Chief Compliance Officer | 2026-05-14 | D | 3,231 | 198 | 640,061 | Common | Form 4 ↗ |
| James Hearty | Chief Compliance Officer | 2026-05-14 | A | 5,784 | 111 | 639,884 | Common | Form 4 ↗ |
| James Hearty | Chief Compliance Officer | 2026-05-15 | D | 15,000 | 194 | 2,909,745 | Common, open-market sale | Form 4 ↗ |
| Adam H. Schechter | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Barbara J. Desoer | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Dennis W. Pullin | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Jason M. Hollar | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Phyllis R. Yale | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Pamela M. Arway | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Gregory J. Moore | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Wendy L. Schoppert | Director | 2026-05-15 | A | 250 | 0 | 0 | Common | Form 4 ↗ |
| Phyllis R. Yale | Director | 2026-05-26 | D | 5,038 | 0 | 0 | Common | Form 4 ↗ |
| Javier Rodriguez | Director | 2026-06-15 | D | 30,000 | 210 | 6,285,090 | Common, open-market sale | Form 4 ↗ |
| Kathleen Waters | Chief Legal & Pub. Affairs Off | 2026-06-15 | D | 6,455 | 209 | 1,350,173 | Common, open-market sale | Form 4 ↗ |
| Kathleen Waters | Chief Legal & Pub. Affairs Off | 2026-06-15 | D | 8,950 | 208 | 1,860,204 | Common, open-market sale | Form 4 ↗ |
| Javier Rodriguez | Director | 2026-06-16 | D | 39,407 | 209 | 8,247,018 | Common, open-market sale | Form 4 ↗ |
| BERKSHIRE HATHAWAY INC | Greater-than-10% holder | 2026-07-31 | D | 182,980 | 200 | 36,513,293 | Common, indirect | Form 4 ↗ |
| Phyllis R. Yale | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Barbara J. Desoer | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Pamela M. Arway | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Dennis W. Pullin | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Adam H. Schechter | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Jason M. Hollar | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Gregory J. Moore | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| Wendy L. Schoppert | Director | 2026-08-15 | A | 278 | 0 | 0 | Common | Form 4 ↗ |
| David Maughan | Chief Operating Officer, DKC | 2026-09-22 | D | 7,501 | 182 | 1,367,732 | Common | Form 4 ↗ |
| BERKSHIRE HATHAWAY INC | Greater-than-10% holder | 2026-10-27 | D | 382,563 | 180 | 69,026,033 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (105 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Javier Rodriguez. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table” · page 51. As printed: 18,210,597. View filing ↗
- Section 01, Joel Ackerman. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table”. As printed: 6,129,962. View filing ↗
- Section 01, David Maughan. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table”. As printed: 5,592,259. View filing ↗
- Section 01, Kathleen Waters. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table”. As printed: 3,943,645. View filing ↗
- Section 01, James Hearty. DEF 14A, filed 2026-04-22. Section “2025 Summary Compensation Table”. As printed: 1,962,115. View filing ↗
- Section 03, Javier Rodriguez PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, David Maughan RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, David Maughan PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Joel Ackerman PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kathleen Waters PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Hearty PSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kathleen Waters RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Hearty RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Javier Rodriguez RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Javier Rodriguez OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Joel Ackerman RSU. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kathleen Waters OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, Joel Ackerman OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, David Maughan OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 03, James Hearty OPTION. DEF 14A, filed 2026-04-22. Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-22. Section “CEO Pay Ratio”. As printed: 254 : 1. View filing ↗
- Section 08, Pamela M. Arway. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 502,449. View filing ↗
- Section 08, Barbara J. Desoer. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 389,949. View filing ↗
- Section 08, Phyllis R. Yale. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 379,949. View filing ↗
- Section 08, Gregory J. Moore, M.D., Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 379,949. View filing ↗
- Section 08, Jason M. Hollar. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 377,449. View filing ↗
- Section 08, Wendy L. Schoppert. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 339,949. View filing ↗
- Section 08, Adam H. Schechter. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 337,449. View filing ↗
- Section 08, Dennis W. Pullin. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 322,449. View filing ↗
- Section 08, Charles G. Berg. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 194,394. View filing ↗
- Section 08, Javier J. Rodriguez. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, BERKSHIRE HATHAWAY INC 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Hearty 2026-05-06. Form 4, filed 2026-05-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joel Ackerman 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Maughan 2026-05-11. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Maughan 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Hearty 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Hearty 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Hearty 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Hearty 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Hearty 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam H. Schechter 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barbara J. Desoer 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis W. Pullin 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Hollar 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis R. Yale 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pamela M. Arway 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory J. Moore 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy L. Schoppert 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis R. Yale 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen Waters 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen Waters 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Javier Rodriguez 2026-06-16. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BERKSHIRE HATHAWAY INC 2026-07-31. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phyllis R. Yale 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Barbara J. Desoer 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Pamela M. Arway 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis W. Pullin 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam H. Schechter 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Hollar 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gregory J. Moore 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy L. Schoppert 2026-08-15. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Maughan 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BERKSHIRE HATHAWAY INC 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-08. Item 5.07 · say-on-pay result. As reported: 98.52% (votes for as printed: 51,716,491). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-09. Item 5.07 · say-on-pay result. As reported: 94.39% (votes for as printed: 59,322,425). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-10. Item 5.07 · say-on-pay result. As reported: 94.79% (votes for as printed: 67,973,191). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,488,132 + equity 1,735,854 + all other 0 = 3,223,986, summed across the director compensation table rows.
- Tenet Healthcare, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Tenet Healthcare's own proxy. As printed: 43,108,969. View filing ↗
- Baxter International, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Baxter International's own proxy. As printed: 29,805,182. View filing ↗
- Iqvia Holdings, Section 10b CEO total. DEF 14A, filed 2026-02-27. CEO total compensation as printed in Iqvia Holdings's own proxy. As printed: 28,128,245. View filing ↗
- HCA Healthcare, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in HCA Healthcare's own proxy. As printed: 26,456,606. View filing ↗
- Centene, Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Centene's own proxy. As printed: 19,506,298. View filing ↗
- Molina Healthcare, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Molina Healthcare's own proxy. As printed: 18,340,783. View filing ↗
- Labcorp Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Labcorp Holdings Inc.'s own proxy. As printed: 18,339,913. View filing ↗
- Davita Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Davita Inc's own proxy. As printed: 18,210,597. View filing ↗
- Universal Health Services, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Universal Health Services's own proxy. As printed: 16,148,937. View filing ↗
- Zimmer Biomet Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Zimmer Biomet Holdings's own proxy. As printed: 16,106,550. View filing ↗
- Hologic, Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic's own proxy. As printed: 15,819,261. View filing ↗
- Quest Diagnostics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Quest Diagnostics's own proxy. As printed: 15,498,479. View filing ↗
- Revvity, Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Revvity's own proxy. As printed: 13,809,549. View filing ↗
- Henry Schein, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Henry Schein's own proxy. As printed: 12,013,915. View filing ↗
- Encompass Health, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Encompass Health's own proxy. As printed: 10,297,258. View filing ↗
- Dentsply Sirona, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Dentsply Sirona's own proxy. As printed: 8,760,139. View filing ↗
- Avantor, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Avantor's own proxy. As printed: 5,895,624. View filing ↗
- Select Medical Holdings, Section 10b CEO total. DEF 14A, filed 2026-03-04. CEO total compensation as printed in Select Medical Holdings's own proxy. As printed: 3,042,527. View filing ↗
- Section 10a, IQVIA Holdings reciprocity. DEF 14A. IQVIA Holdings's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Hologic reciprocity. DEF 14A. Hologic's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Tenet Healthcare reciprocity. DEF 14A. Tenet Healthcare names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Centene reciprocity. DEF 14A. Centene's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Labcorp Holdings Inc. reciprocity. DEF 14A. Labcorp Holdings Inc.'s most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Revvity reciprocity. DEF 14A. Revvity's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Avantor reciprocity. DEF 14A. Avantor's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Baxter International reciprocity. DEF 14A. Baxter International names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Dentsply Sirona reciprocity. DEF 14A. Dentsply Sirona's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Encompass Health reciprocity. DEF 14A. Encompass Health names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, HCA Healthcare reciprocity. DEF 14A. HCA Healthcare's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗
- Section 10a, Henry Schein reciprocity. DEF 14A. Henry Schein names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Molina Healthcare reciprocity. DEF 14A. Molina Healthcare names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Quest Diagnostics reciprocity. DEF 14A. Quest Diagnostics names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Universal Health Services reciprocity. DEF 14A. Universal Health Services names Davita Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Zimmer Biomet Holdings reciprocity. DEF 14A. Zimmer Biomet Holdings's most recent proxy was read; its disclosed peer group does not include Davita Inc. View filing ↗